ADDICTIVE DISORDERS: Edited by John B. Saunders and Linda B. CottlerGlobal strategy for New Psychoactive Substances: an updateVicknasingam, Balasingama; Narayanan, Sureshb; Singh, Darshana; Corazza, OrnellacAuthor Information aCentre for Drug Research, Universiti Sains Malaysia bSchool of Social Sciences, Universiti Sains Malaysia, Minden, Penang, Malaysia cDepartment of Clinical and Pharmaceutical Sciences, University of Hertfordshire, Hatfield, United Kingdom Correspondence to Balasingam Vicknasingam, PhD, Centre for Drug Research, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia. E-mail: firstname.lastname@example.org Current Opinion in Psychiatry: July 2020 - Volume 33 - Issue 4 - p 295-300 doi: 10.1097/YCO.0000000000000612 Buy Metrics Abstract Purpose of review The aim of this review is to provide an update on recent trends of New Psychoactive Substances (NPS) and the current global strategies implemented to manage them. Recent findings The number of NPS has increased from 166 in 2009 to 892 in 2018, with about 36% having stimulant effects. Such trend revels some unprecedented patterns. The decline in the emergence of new synthetic cannabinoids has coincided with rising deaths due to overdose of fentanyl and non-fentanyl compounds in North America and Europe. The detection of new stimulant NPS has stabilized since 2015. Although the level of seizures of mephedrone have risen since then, they are still below the levels reported before international control. The legal status of kratom still remains unclear, whereas calls for research on its benefits continue. The nonmedical use of tramadol in Africa and Middle East is a cause of growing concern. Summary Although the rise of NPS is a cause for concern, evidence suggests that the strategy to face the challenge should include updating international data collection systems, integrating scientific-based interventions for drug use, strengthening national monitoring, and increasing collaborative research and forensic capabilities. The legal, regulatory framework and clinical guidelines should remain dynamic, whereas enforcement agencies should measure success by destroying drug networks as seizures rarely dismantle drug markets. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.